[HTML][HTML] Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma
A Méjean, A Ravaud, S Thezenas… - … England Journal of …, 2018 - Mass Medical Soc
Background Cytoreductive nephrectomy has been the standard of care in metastatic renal-
cell carcinoma for 20 years, supported by randomized trials and large, retrospective studies.
However, the efficacy of targeted therapies has challenged this standard. We assessed the
role of nephrectomy in patients with metastatic renal-cell carcinoma who were receiving
targeted therapies. Methods In this phase 3 trial, we randomly assigned, in a 1: 1 ratio,
patients with confirmed metastatic clear-cell renal-cell carcinoma at presentation who were …
cell carcinoma for 20 years, supported by randomized trials and large, retrospective studies.
However, the efficacy of targeted therapies has challenged this standard. We assessed the
role of nephrectomy in patients with metastatic renal-cell carcinoma who were receiving
targeted therapies. Methods In this phase 3 trial, we randomly assigned, in a 1: 1 ratio,
patients with confirmed metastatic clear-cell renal-cell carcinoma at presentation who were …
Re: Sunitinib Alone or after Nephrectomy in Metastatic Renal-cell Carcinoma.
… Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. Eur Urol 2018;74:842-3:
Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with
Immunocheckpoint Inhibitors for Renal Cell Carcinoma." Eur Urol. 2019 Mar;75(3):e64-e66. …
N Engl J Med 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive
Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma? …
Lymphocyte Phenotype and Timing of Radical Nephrectomy in Patients Treated with
Immunocheckpoint Inhibitors for Renal Cell Carcinoma." Eur Urol. 2019 Mar;75(3):e64-e66. …
N Engl J Med 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive
Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma? …
以上显示的是最相近的搜索结果。 查看全部搜索结果